Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

21e66f0f-e49d-4e75-bc70-f1d248c1b947

—

7b2c1673-426b-5008-8bfb-e94e69e81686

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.400
  • ANGIOGENESIS+0.300
  • HEDGEHOG_SIGNALING+0.300
  • MYOGENESIS+0.300
  • P53_PATHWAY+0.300
  • WNT_BETA_CATENIN_SIGNALING+0.300
  • ADIPOGENESIS+0.200
  • APICAL_JUNCTION+0.200
  • APOPTOSIS+0.200
  • DNA_REPAIR+0.200

Top 10 suppressed

  • INTERFERON_GAMMA_RESPONSE-0.200
  • INTERFERON_ALPHA_RESPONSE-0.100
  • KRAS_SIGNALING_DN-0.100
  • PROTEIN_SECRETION-0.100
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.100
  • ALLOGRAFT_REJECTION+0.000
  • ANDROGEN_RESPONSE+0.000
  • APICAL_SURFACE+0.000
  • BILE_ACID_METABOLISM+0.000
  • CHOLESTEROL_HOMEOSTASIS+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
182990
medullo-epn-umap@date-based
EPNSupratentorial EPN0.719
2SRR8943009
bladder-landscape@3
——0.711
3TCGA-18-3417-01A-01R-1443-07
lung-landscapes@6
—cohortSQ10.709
4SRR8518155
breast-umap@18
—E0.695
5SRR27320688
colon-landscapes@1
——0.693
6TCGA-34-5236-01A-21R-1820-07
lung-landscapes@6
—cohortSQ10.687
7SRR2771207
melanoma-umap@29
——0.682
8TCGA-60-2708-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.677
9BS_23QW0BBA
brain-umap@2
high-grade glioma—0.677
10C3L-02130
lung-landscapes@6
—cohortSQ10.671

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.400Cobimetinib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
P53_PATHWAY0.300Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
APICAL_JUNCTION0.200Inavolisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
DNA_REPAIR0.200Idelalisib— uncovered
E2F_TARGETS0.200Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.200Inavolisib— uncovered
HYPOXIA0.200Idelalisib— uncovered
MYC_TARGETS_V10.200Inavolisib— uncovered
NOTCH_SIGNALING0.200Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
UV_RESPONSE_UP0.200Idelalisib— uncovered
COAGULATION0.100Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.100Inavolisib— uncovered